US drugmaker Bristol Myers Squibb (NYSE: BMY) was trading 2% higher at lunchtime Thursday after presenting its fourth quarter and full year 2022 financial results.
The company’s adjusted earnings per share (EPS) for the fourth quarter of 2022 came in at $1.82. This was 1% down on the same period of 2021, but well ahead of the FactSet consensus of $1.73.
"Well-positioned for multiple waves of innovation"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze